Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666900 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by Dow Pharmaceutical Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
- 20
- Study locations
NCT00666900 is a Phase 2 study of Acne Vulgaris that has completed, run by Dow Pharmaceutical Sciences. The registered enrollment target is 366 participants, above the 270-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (36% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT00666900, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Dow Pharmaceutical Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.
Conditions Studied
Interventions
- DRUG Placebo Comparator
- DRUG Low Strength IDP-107
- DRUG High Strength IDP-107
Study Locations (20)
California
- RADY Children's Hospital - San Diego - San Diego
- Clinical Science Institute - Santa Monica
- Solano Clinical Research - Vallejo
Texas
- Arlington Research Center, Inc. - Arlington
- DermResearch, Inc. - Austin
- J & S Studies, Inc. - Bryan
Arkansas
- Burke Pharmaceutical Research - Hot Springs
- Dermatology Research of Arkansas, PLLC - Little Rock
Michigan
- Michigan Center for Skin Care Research - Clinton Township
- Hamzavi Dermatology - Fort Gratiot
New York
- Dermatology Associates of Rochester - Rochester
- DermResearchCenter of New York, Inc. - Stony Brook
Colorado
- Cherry Creek Research, Inc. - Denver
Florida
- FXM Research Corp. - Miami
Minnesota
- Minnesota Clinical Study Center - Fridley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666900
The ClinicalTrials.gov registry entry for NCT00666900 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 270-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (36% higher). The listed sponsor is Dow Pharmaceutical Sciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT00666900 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Texas, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00666900 about?
NCT00666900 is a clinical study titled "A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris". The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.
What is the current status of trial NCT00666900?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2008-01. Estimated completion is 2009-09.
What conditions does trial NCT00666900 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT00666900?
The interventions under investigation include: Placebo Comparator (DRUG), Low Strength IDP-107 (DRUG), High Strength IDP-107 (DRUG).
Who is sponsoring clinical trial NCT00666900?
This trial is sponsored by Dow Pharmaceutical Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00666900 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.